Video

New Data for Newly Diagnosed Myeloma

Transcript:Keith Stewart, MB, CHB: Let’s move on now. We’ll talk about how we treat newly-diagnosed symptomatic patients. So, these are patients who clearly need therapy. Saad, we’ll start with you. What factors do you consider when determining the most appropriate upfront therapy for your younger transplant-eligible patients?

Saad Usmani, MD: The general approach for the transplant-eligible patients is a triplet regimen across the board.

Keith Stewart, MB, CHB: Triplet of what?

Saad Usmani, MD: Of lenalidomide/bortezomib/dexamethasone (RVD). There are certain situations where you need therapy quickly, for example, a patient who is presenting with renal insufficiency, getting admitted to the hospital, and that’s how they’re being diagnosed. You might reach for a regimen that includes bortezomib/cyclophosphamide/dexamethasone to begin with.

Keith Stewart, MB, CHB: So, patients with renal failure, for example?

Saad Usmani, MD: Yes, yes. Generally, the goal is to try to induce cytoreduction fairly quickly, and try to get them to as best a response as you can before taking them to a transplant.

Keith Stewart, MB, CHB: This combination of RVD seems to have become de facto standard, in North America, at least. Is anybody using anything different in their newly-diagnosed patients, outside of trials, just in routine practice?

Paul Richardson, MD: Well, I think in the context of triplets, I completely agree with Saad. The question then becomes the 4-drug regimens and what might you use. And we’ve been participating in a variety of studies—actually in partnership with Sagar—looking at the addition of HDAC (histone deacetylase) inhibitors to the 3-drug platform. For example, now with the approval of panobinostat, there’s the use of panobinostat with RVD after Jatin Shah’s very important work, and prior to that, Sagar and Jonathan’s work with RVD/vorinostat. And we’re comfortable deploying HDAC inhibitors earlier off protocol in patients who we think might be at higher risk.

Keith Stewart, MB, CHB: And there are some new oral drugs that can be considered. I think you’ve got some experience, Amrita, with ixazomib and use with lenalidomide/dexamethasone. Can you speak to that a little bit?

Amrita Krishnan, MD: Certainly. You’re right, oral drugs are very attractive to patients, especially early in the stage of their disease. It’s been well tolerated. For example, the ixazomib/lenalidomide/dexamethasone regimen has induced deep remissions, long responses. I have someone who has been on it for 5 years, right now. Just to Paul’s point though, in terms of additional agents, I do want to mention immunotherapy, as well, in the early upfront setting.

Keith Stewart, MB, CHB: Such as what?

Amrita Krishnan, MD: Well, Saad has a trial, that we participated in, adding elotuzumab to an RVD backbone for high-risk patients. And, certainly, we are opening a trial with the addition of daratumumab to an RVD backbone. So, I think when the immune system is more intact, that is a good time to intervene with these agents.

Keith Stewart, MB, CHB: These are mostly clinical trials at this point, though, that I think is fair to emphasize. Before we leave the triplets, I’m assuming that most people would preserve the all-oral regimen like ixazomib for a more elderly population? We don’t want to neglect that group of patients, so what would you treat an elderly patient with today who came in with newly-diagnosed myeloma?

Sagar Lonial, MD: I think what everybody is summarizing is the idea that an IMiD/PI (proteasome inhibitor) represents probably the best backbone. And, I think, in the United States, the IMiD would be lenalidomide. As for the PI, it really depends.

Transcript Edited for Clarity

Related Videos
Ajay K. Nooka, MD, MPH, FACP
Meletios A. Dimopoulos, MD
Binod Dhakal, MD
In this final episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, Drs Usmani and Wasil, discuss plans for developing guidelines and policies to enhance management of bispecific T-cell engagers across various centers.
In this episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, Drs Usmani and Wasil discuss the need for continued evaluation of prophylactic treatments like tocilizumab (Actemra) and antimicrobial measures for bispecific T-cell engagers, noting logistical and financial challenges and the importance of collaboration with community centers.
In this episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, Drs Usmani and Wasil emphasize the need for comprehensive patient education, effective communication, and specific safety protocols to manage patients receiving bispecific T-cell engagers.
In this episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, Drs Usmani and Wasil discuss the challenges and strategies in managing bispecific T-cell engagers in the realm of cancer, emphasizing the importance of community and tertiary care collaboration to handle unique toxicities like cytokine release syndrome (CRS) and the need for well-defined protocols to ensure patient safety and effective treatment.
In this episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, Drs Usmani and Wasil discuss bispecific T-cell engagers, highlighting their effectiveness in treating hematologic malignancies like multiple myeloma, their potential use in solid tumors, and the importance of managing unique adverse effects, such as cytokine release syndrome and infection risks.
Jill Corre, PharmD, PhD
Jill Corre, PharmD, PhD